Ignite Creation Date:
2025-12-24 @ 5:26 PM
Ignite Modification Date:
2026-03-28 @ 11:33 AM
Study NCT ID:
NCT02720068
Status:
COMPLETED
Last Update Posted:
2025-05-30
First Post:
2016-03-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-05-02
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-03-15
Completion Date Type:
ACTUAL
First Submit Date:
2016-03-22
First Submit QC Date:
None
Study First Post Date:
2016-03-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2025-03-04
Results First Submit QC Date:
None
Results First Post Date:
2025-05-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-28
Last Update Post Date:
2025-05-30
Last Update Post Date Type:
ACTUAL